- Home
- TNGX vs MGPI Comparison
TNGX vs MGPI Comparison
Compare TNGX & MGPI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNGX
- MGPI
- Stock Information
- Founded
- TNGX 2014
- MGPI 1941
- Country
- TNGX United States
- MGPI United States
- Employees
- TNGX N/A
- MGPI N/A
- Industry
- TNGX Biotechnology: Pharmaceutical Preparations
- MGPI Beverages (Production/Distribution)
- Sector
- TNGX Health Care
- MGPI Consumer Staples
- Exchange
- TNGX Nasdaq
- MGPI Nasdaq
- Market Cap
- TNGX 735.0M
- MGPI N/A
- IPO Year
- TNGX N/A
- MGPI 1988
- Fundamental
- Price
- TNGX $6.64
- MGPI $57.57
- Analyst Decision
- TNGX Strong Buy
- MGPI Strong Buy
- Analyst Count
- TNGX 8
- MGPI 4
- Target Price
- TNGX $15.14
- MGPI $92.00
- AVG Volume (30 Days)
- TNGX 885.7K
- MGPI 386.3K
- Earning Date
- TNGX 11-06-2024
- MGPI 10-31-2024
- Dividend Yield
- TNGX N/A
- MGPI 0.83%
- EPS Growth
- TNGX N/A
- MGPI N/A
- EPS
- TNGX N/A
- MGPI 4.33
- Revenue
- TNGX $42,509,000.00
- MGPI $787,880,000.00
- Revenue This Year
- TNGX $18.15
- MGPI N/A
- Revenue Next Year
- TNGX N/A
- MGPI $4.62
- P/E Ratio
- TNGX N/A
- MGPI $13.27
- Revenue Growth
- TNGX 26.16
- MGPI N/A
- 52 Week Low
- TNGX $6.33
- MGPI $56.52
- 52 Week High
- TNGX $13.01
- MGPI $102.42
- Technical
- Relative Strength Index (RSI)
- TNGX 37.15
- MGPI 14.38
- Support Level
- TNGX $6.83
- MGPI $78.93
- Resistance Level
- TNGX $7.47
- MGPI $81.67
- Average True Range (ATR)
- TNGX 0.37
- MGPI 2.58
- MACD
- TNGX 0.11
- MGPI -2.37
- Stochastic Oscillator
- TNGX 27.31
- MGPI 3.02
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.